Clinical trial

Effect of MD1003 in Spinal Progressive Multiple Sclerosis

NCT02220933

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2013-10-01

PhasePHASE3

Study timeline

Study start (actual)2013-10-01Date precision: month

Registry last updated2017-03-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

MD1003 100mg capsuleDRUG

PlaceboDRUG

Sponsors & collaborators

MedDay Pharmaceuticals SAlead sponsor

Mapped research locations

ParisFrance2 ToulouseFrance1 MarseilleFrance1 MontpellierFrance1 LyonFrance1 StrasbourgFrance1 BordeauxFrance1 NantesFrance1 RennesFrance1 NiceFrance1 DijonFrance1 CaenFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02220933 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.